MCID: PRM042
MIFTS: 61

Primary Effusion Lymphoma

Categories: Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Primary Effusion Lymphoma

MalaCards integrated aliases for Primary Effusion Lymphoma:

Name: Primary Effusion Lymphoma 49 55 69
Pel 49 55
Body Cavity-Based Lymphoma 55
Lymphoma, Aids-Related 69
Aids-Related Lymphoma 49
Lymphoma Aids-Related 51

Characteristics:

Orphanet epidemiological data:

55
primary effusion lymphoma
Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 55 ORPHA48686
MESH via Orphanet 42 D054685
UMLS via Orphanet 70 C1292753
ICD10 via Orphanet 33 C83.8

Summaries for Primary Effusion Lymphoma

MalaCards based summary : Primary Effusion Lymphoma, also known as pel, is related to human herpesvirus 8 and kaposi sarcoma, and has symptoms including pericardial effusion, abdominal pain and dyspnea. An important gene associated with Primary Effusion Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Doxorubicin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and liver, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 72 Primary effusion lymphoma (PEL) is a B-cell lymphoma, presenting with a malignant effusion without a... more...

Related Diseases for Primary Effusion Lymphoma

Diseases related to Primary Effusion Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 32.3 BCL6 IL6
2 kaposi sarcoma 30.8 AKT1 IL6 MYC STAT3 VEGFA
3 multicentric castleman disease 30.0 BCL6 IL6
4 follicular lymphoma 29.5 BCL6 IRF4 MYC
5 diffuse large b-cell lymphoma 29.1 BCL6 IRF4 MYC STAT3
6 b-cell lymphomas 28.8 BCL6 CASP3 CDKN1B IRF4 MYC TCL1A
7 myeloma, multiple 27.4 AKT1 CASP3 IL6 IRF4 MYC STAT3
8 hepatocellular carcinoma 27.4 AKT1 CASP3 IL6 MYC STAT3 TNFSF10
9 lymphoma aids related 11.6
10 plasmablastic lymphoma 11.4
11 lymphoma 11.0
12 pelger-huet anomaly 10.9
13 sarcoma 10.6
14 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.3 BCL6 MYC
15 critical limb ischemia 10.3 IL6 VEGFA
16 spinal disease 10.3 IL6 VEGFA
17 poems syndrome 10.2 IL6 VEGFA
18 primary mediastinal large b-cell lymphoma 10.2 BCL6 IRF4
19 hepatitis 10.2
20 colon lymphoma 10.2 BCL6 IRF4
21 gastric lymphoma 10.2 BCL6 VEGFA
22 lymphangiosarcoma 10.2 MYC VEGFA
23 hepatitis c 10.1
24 hepatitis c virus 10.1
25 osteogenic sarcoma 10.1 CASP3 MYC TNFSF10
26 peritonitis 10.0
27 liver cirrhosis 10.0
28 nervous system disease 10.0 CASP3 IL6 VEGFA
29 castleman disease 10.0
30 endotheliitis 10.0
31 acquired immunodeficiency syndrome 10.0 BCL6 IL6 MYC
32 macular retinal edema 10.0 IL6 VEGFA
33 mixed lacrimal gland cancer 9.9 IL6 STAT3
34 peripheral t-cell lymphoma 9.9 BCL6 TCL1A
35 peripheral nervous system neoplasm 9.9 AKT1 CASP3 MYC
36 ovarian cancer 1 9.9 AKT1 CASP3 VEGFA
37 autonomic nervous system neoplasm 9.9 AKT1 CASP3 MYC
38 hepatitis b 9.9
39 immune suppression 9.9 IL6 STAT3
40 leukemia, chronic myeloid 9.9 AKT1 CASP3 MYC
41 astrocytoma 9.8 AKT1 IL6 VEGFA
42 sensory system cancer 9.8 AKT1 CDKN1B MYC
43 autoimmune lymphoproliferative syndrome, type v 9.8
44 cardiac tamponade 9.8
45 cowpox 9.8 CASP3 IL6
46 apical myocardial infarction 9.8 AKT1 STAT3
47 male reproductive organ cancer 9.8 AKT1 CASP3 MYC VEGFA
48 female reproductive organ cancer 9.7 AKT1 CASP3 MYC VEGFA
49 cell type cancer 9.7 AKT1 CASP3 MYC VEGFA
50 t-cell prolymphocytic leukemia 9.7 CDKN1B MYC TCL1A VEGFA

Graphical network of the top 20 diseases related to Primary Effusion Lymphoma:



Diseases related to Primary Effusion Lymphoma

Symptoms & Phenotypes for Primary Effusion Lymphoma

Human phenotypes related to Primary Effusion Lymphoma:

55 31 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pericardial effusion 55 31 hallmark (90%) Very frequent (99-80%) HP:0001698
2 abdominal pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 dyspnea 55 31 hallmark (90%) Very frequent (99-80%) HP:0002094
4 pleural effusion 55 31 hallmark (90%) Very frequent (99-80%) HP:0002202
5 abnormality of the peritoneum 55 31 hallmark (90%) Very frequent (99-80%) HP:0002585
6 immunodeficiency 55 31 frequent (33%) Frequent (79-30%) HP:0002721
7 abdominal distention 55 31 hallmark (90%) Very frequent (99-80%) HP:0003270
8 b-cell lymphoma 55 31 hallmark (90%) Very frequent (99-80%) HP:0012191

MGI Mouse Phenotypes related to Primary Effusion Lymphoma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 CDKN1B BCL6 CASP3 AKT1 MYC IL6
2 hematopoietic system MP:0005397 10.19 CASP3 AKT1 CDKN1B BCL6 IRF4 MYC
3 endocrine/exocrine gland MP:0005379 10.18 CASP3 AKT1 CDKN1B BCL6 MYC IL6
4 immune system MP:0005387 10.16 CDKN1B BCL6 CASP3 AKT1 IRF4 MYC
5 cellular MP:0005384 10.15 BCL6 CASP3 AKT1 STAT3 CDKN1B MYC
6 homeostasis/metabolism MP:0005376 10.13 BCL6 CDKN1B CASP3 AKT1 STAT3 MYC
7 growth/size/body region MP:0005378 10.11 BCL6 CASP3 AKT1 STAT3 CDKN1B MYC
8 mortality/aging MP:0010768 10.02 BCL6 CDKN1B CASP3 AKT1 STAT3 MYC
9 digestive/alimentary MP:0005381 10.01 CDKN1B CASP3 STAT3 MYC IL6 VEGFA
10 liver/biliary system MP:0005370 10.01 AKT1 CDKN1B BCL6 MYC IL6 STAT3
11 integument MP:0010771 9.98 CDKN1B CASP3 AKT1 STAT3 MYC IL6
12 adipose tissue MP:0005375 9.97 AKT1 STAT3 CDKN1B MYC IL6
13 muscle MP:0005369 9.92 BCL6 CASP3 AKT1 CDKN1B MYC IL6
14 neoplasm MP:0002006 9.86 AKT1 CDKN1B IRF4 MYC IL6 STAT3
15 reproductive system MP:0005389 9.81 CASP3 AKT1 CDKN1B BCL6 MYC IL6
16 respiratory system MP:0005388 9.5 CDKN1B BCL6 CASP3 AKT1 IL6 STAT3
17 skeleton MP:0005390 9.23 CDKN1B CASP3 AKT1 MYC IL6 STAT3

Drugs & Therapeutics for Primary Effusion Lymphoma

Drugs for Primary Effusion Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
2
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
3
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
4
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
5
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
6
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
7
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
8
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Zidovudine Approved Phase 2 30516-87-1 35370
10
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
11
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
12
Allopurinol Approved Phase 2 315-30-0 2094
13
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
14
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
15
Ifosfamide Approved Phase 2 3778-73-2 3690
16
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
17
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
18
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Sulfamethoxazole Approved Phase 2 723-46-6 5329
21
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
22
Trimethoprim Approved, Vet_approved Phase 2 738-70-5 5578
23
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
24
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
25
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
26
Bevacizumab Approved, Investigational Phase 2 216974-75-3
27
Fluorouracil Approved Phase 2 51-21-8 3385
28
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
29
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
30
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
31
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
32
Cortisone acetate Approved, Investigational Phase 1, Phase 2 1950-04-4, 50-04-4 5745
33
nivolumab Approved Phase 2 946414-94-4
34
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
35
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
37
Doxil Approved June 1999 Phase 2,Phase 1 31703
38 Prednisolone acetate Phase 2
39 Isophosphamide mustard Phase 2 0
40 Alkylating Agents Phase 2,Phase 1
41 glucocorticoids Phase 2,Phase 1
42 Renal Agents Phase 2
43 Methylprednisolone acetate Phase 2
44 Methylprednisolone Hemisuccinate Phase 2
45 Reverse Transcriptase Inhibitors Phase 2
46 Adjuvants, Immunologic Phase 2,Phase 1
47 Folic Acid Antagonists Phase 2
48 Ganciclovir triphosphate Phase 2
49 Gastrointestinal Agents Phase 2
50 Neuroprotective Agents Phase 2

Interventional clinical trials:

(show all 32)

# Name Status NCT ID Phase Drugs
1 Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma Completed NCT00217503 Phase 2 bortezomib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ganciclovir;valganciclovir;zidovudine
2 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
3 SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002571 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;prednisone;trimethoprim-sulfamethoxazole;vincristine sulfate;Intrathecal cytarabine
4 Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma Completed NCT00005824 Phase 2 busulfan;cyclophosphamide
5 EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2 EPOCH
6 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00003388 Phase 2 cyclophosphamide;cytarabine;methotrexate;pegylated liposomal doxorubicin hydrochloride;prednisone;vincristine sulfate
7 A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL Completed NCT00799136 Phase 2 R-EPOCH and cART
8 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Completed NCT00858793 Phase 1, Phase 2
9 Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Completed NCT00003114 Phase 2 cyclophosphamide;etoposide;lomustine;procarbazine hydrochloride
10 Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2 Lenalidomide;Rituximab;Prednisone;Etopside;Doxorubicin;Vincristine;Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
11 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
12 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting NCT01193842 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate;Vorinostat
13 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma Suspended NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;cyclophosphamide;procarbazine hydrochloride
14 Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma Terminated NCT00126243 Phase 2 rituximab;CHOP
15 Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas Terminated NCT00183976 Phase 2 Pegylated Liposomal Doxorubicin (Doxil) and Rituximab
16 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
17 Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma Withdrawn NCT00024128 Phase 2 cyclophosphamide;cyclosporine
18 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Withdrawn NCT00310128 Phase 2 cisplatin;cytarabine;etoposide;methylprednisolone;rituximab;yttrium Y 90 ibritumomab tiuxetan
19 Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Recruiting NCT03220022 Phase 1 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ibrutinib;Prednisone;Vincristine Sulfate
20 Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Recruiting NCT02337985 Phase 1 Prednisone;Etoposide;Doxorubicin Hydrochloride;Vincristine Sulfate;Cyclophosphamide
21 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting NCT02924402 Phase 1
22 Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma Active, not recruiting NCT00569985 Phase 1 carmustine;cyclophosphamide;etoposide
23 Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting NCT01961063 Phase 1 busulfan
24 Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757614
25 Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States Completed NCT00026728
26 Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members Completed NCT00000703 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Zidovudine;Dexamethasone
27 Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma Recruiting NCT02823327
28 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
29 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Recruiting NCT02652715
30 124I-FIAU Imaging in EBV and KSHV Associated Cancers Recruiting NCT00982449 Early Phase 1
31 Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Withdrawn NCT01769911 carmustine;cytarabine;melphalan;etoposide;O6-benzylguanine
32 Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer Withdrawn NCT00499668 aprepitant;ondansetron hydrochloride

Search NIH Clinical Center for Primary Effusion Lymphoma

Genetic Tests for Primary Effusion Lymphoma

Anatomical Context for Primary Effusion Lymphoma

MalaCards organs/tissues related to Primary Effusion Lymphoma:

38
B Cells, T Cells, Liver, Endothelial, Heart, Brain, Testis

Publications for Primary Effusion Lymphoma

Articles related to Primary Effusion Lymphoma:

(show top 50) (show all 412)
# Title Authors Year
1
Arctigenin induces the apoptosis of primary effusion lymphoma cells under conditions of glucose deprivation. ( 29207179 )
2018
2
Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models. ( 29207182 )
2018
3
Cytokeratin-positive primary effusion lymphoma: a diagnostic challenge. ( 28880367 )
2017
4
Primary effusion lymphoma: current concepts and management. ( 28399009 )
2017
5
Rapidly progressive intravascular primary effusion lymphoma in an HIV-positive renal transplant recipient. ( 28815752 )
2017
6
HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. ( 28705937 )
2017
7
Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma. ( 28481873 )
2017
8
Correction for Cousins and Nicholas, "Role of Human Herpesvirus 8 Interleukin-6-Activated gp130 Signal Transducer in Primary Effusion Lymphoma Cell Growth and Viability". ( 29191994 )
2017
9
Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder. ( 29105119 )
2017
10
1, 25(OH)2 D3 Induces Reactivation and Death of Kaposi's Sarcoma-Associated Herpesvirus of Primary Effusion Lymphoma cells. ( 28963501 )
2017
11
Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy. ( 28580733 )
2017
12
YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma. ( 28396094 )
2017
13
Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. ( 28922425 )
2017
14
Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. ( 28092744 )
2017
15
Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. ( 28468596 )
2017
16
Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma. ( 28146424 )
2017
17
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. ( 28459467 )
2017
18
Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma. ( 28407694 )
2017
19
Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma. ( 28084853 )
2017
20
Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide. ( 28432410 )
2017
21
Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. ( 28847988 )
2017
22
Primary effusion lymphoma in Taiwan shows two distinctive clinicopathological subtypes with rare human immunodeficiency virus association. ( 29206290 )
2017
23
InA vitro and inA vivo anti-primary effusion lymphoma activities of fucoidan extracted from Cladosiphon okamuranus Tokida. ( 29048633 )
2017
24
Primary effusion lymphoma-like lymphoma with a T cell phenotype. ( 29199356 )
2017
25
Diversity of human herpesvirus 8 genotypes in patients with AIDS and non-AIDS associated Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in Argentina. ( 28617968 )
2017
26
Post-transplant Lymphoproliferative Disorder Presented in a Form of Primary Effusion Lymphoma with t (8; 14). ( 28667038 )
2017
27
Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma presenting with cardiac tamponade: A case report. ( 29068981 )
2017
28
Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. ( 29021516 )
2017
29
SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells. ( 28393364 )
2017
30
Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma. ( 28653223 )
2017
31
Correction for Cousins et al., "Human Herpesvirus 8 Viral Interleukin-6 Signaling through gp130 Promotes Virus Replication in Primary Effusion Lymphoma and Endothelial Cells". ( 29138334 )
2017
32
Epigallocatechin-3-Gallate Suppresses Human Herpesvirus 8 Replication and Induces ROS Leading to Apoptosis and Autophagy in Primary Effusion Lymphoma Cells. ( 29267216 )
2017
33
Expression and subcellular localization of the KSHV K15P protein during latency and lytic reactivation in primary effusion lymphoma cells. ( 28835496 )
2017
34
A Case of Diffuse Large B-Cell Lymphoma Mimicking Primary Effusion Lymphoma-Like Lymphoma. ( 29279707 )
2017
35
A unique case of primary effusion lymphoma-like lymphoma showing disappearance and recurrence of the body cavity effusion. ( 29263988 )
2017
36
An intrasinusoidal extracavitary variant of primary effusion lymphoma. ( 28798059 )
2017
37
Effects of ER stress on unfolded protein responses, cell survival, and viral replication in primary effusion lymphoma. ( 26692493 )
2016
38
Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress. ( 27484211 )
2016
39
Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy? ( 27462227 )
2016
40
Human herpesvirus-8-unrelated primary effusion lymphoma of the elderly not associated with an increased serum lactate dehydrogenase level: A benign sub-group of effusion lymphoma without chemotherapy. ( 26727336 )
2016
41
PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. ( 26625717 )
2016
42
Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience. ( 27521315 )
2016
43
A potential role of the NOD genetic background in mouse peritoneal macrophages for the development of primary effusion lymphoma. ( 26859781 )
2016
44
Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. ( 27414752 )
2016
45
Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells. ( 26821279 )
2016
46
Human Herpes Virus 8 Unrelated Bilateral Primary Effusion Lymphoma in a Patient With Chronic Fluid Overload. ( 27021141 )
2016
47
Successful Treatment of immune Reconstitution Inflammatory syndrome-related Hemophagocytic Syndrome in an HIV Patient with Primary Effusion Lymphoma. ( 28090281 )
2016
48
Diagnostic pitfall: primary effusion lymphoma with rare cytokeratin immunoreactivity. ( 28092872 )
2016
49
Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function. ( 27893813 )
2016
50
Diallyl trisulfide induces apoptosis by suppressing NF-I_B signaling through destabilization of TRAF6 in primary effusion lymphoma. ( 26647777 )
2016

Variations for Primary Effusion Lymphoma

Copy number variations for Primary Effusion Lymphoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas

Expression for Primary Effusion Lymphoma

Search GEO for disease gene expression data for Primary Effusion Lymphoma.

Pathways for Primary Effusion Lymphoma

Pathways related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 AKT1 BCL6 CASP3 CDKN1B IL6 IRF4
2
Show member pathways
13.73 AKT1 CASP3 CDKN1B IL6 MYC STAT3
3
Show member pathways
13.59 AKT1 CASP3 IL6 MYC STAT3 TNFSF10
4
Show member pathways
13.48 AKT1 IL6 MYC STAT3 TNFSF10 VEGFA
5
Show member pathways
13.35 AKT1 CASP3 CDKN1B IL6 STAT3 TNFSF10
6
Show member pathways
13.29 AKT1 CASP3 MYC STAT3 VEGFA
7
Show member pathways
13.25 AKT1 BCL6 CASP3 IL6 IRF4 MYC
8
Show member pathways
12.95 AKT1 CASP3 CDKN1B IL6 MYC STAT3
9
Show member pathways
12.84 AKT1 CASP3 IL6 TNFSF10
10
Show member pathways
12.84 AKT1 CASP3 CDKN1B IL6 MYC TCL1A
11
Show member pathways
12.78 AKT1 CASP3 IRF4 MYC TNFSF10
12
Show member pathways
12.74 AKT1 CDKN1B IL6 MYC STAT3
13
Show member pathways
12.74 AKT1 CASP3 CDKN1B IL6 STAT3 TNFSF10
14 12.72 AKT1 CASP3 MYC VEGFA
15 12.7 AKT1 CASP3 CDKN1B IL6 MYC STAT3
16
Show member pathways
12.63 AKT1 CASP3 TNFSF10 VEGFA
17
Show member pathways
12.58 AKT1 CASP3 TNFSF10 VEGFA
18
Show member pathways
12.57 AKT1 BCL6 MYC STAT3
19
Show member pathways
12.56 IL6 IRF4 MYC STAT3
20
Show member pathways
12.56 AKT1 IL6 MYC STAT3
21
Show member pathways
12.48 AKT1 CASP3 MYC STAT3
22 12.48 CASP3 CDKN1B MYC STAT3 VEGFA
23
Show member pathways
12.46 AKT1 CASP3 MYC STAT3
24
Show member pathways
12.45 AKT1 CDKN1B MYC STAT3 VEGFA
25
Show member pathways
12.38 AKT1 CDKN1B MYC STAT3
26
Show member pathways
12.38 AKT1 CASP3 CDKN1B IL6 MYC STAT3
27
Show member pathways
12.37 AKT1 BCL6 IRF4 MYC
28
Show member pathways
12.33 AKT1 IL6 MYC STAT3
29
Show member pathways
12.32 AKT1 CASP3 IL6 STAT3
30 12.28 AKT1 CDKN1B MYC STAT3
31 12.26 AKT1 CASP3 MYC STAT3 VEGFA
32
Show member pathways
12.24 AKT1 CASP3 CDKN1B STAT3 VEGFA
33 12.23 BCL6 CDKN1B IL6 MYC
34
Show member pathways
12.22 AKT1 CASP3 TNFSF10
35
Show member pathways
12.22 AKT1 CASP3 STAT3
36 12.21 CASP3 MYC TNFSF10
37
Show member pathways
12.2 AKT1 CASP3 CDKN1B MYC
38 12.19 AKT1 CASP3 IL6
39 12.15 CASP3 IL6 VEGFA
40 12.14 AKT1 IL6 MYC
41 12.13 AKT1 CASP3 MYC VEGFA
42
Show member pathways
12.11 AKT1 CASP3 MYC
43
Show member pathways
12.11 AKT1 MYC STAT3
44
Show member pathways
12.09 AKT1 IL6 STAT3
45
Show member pathways
12.09 AKT1 CDKN1B MYC STAT3 VEGFA
46 12.08 AKT1 CASP3 STAT3
47 12.06 AKT1 MYC STAT3
48 12.06 IL6 MYC STAT3 VEGFA
49 12.06 AKT1 CASP3 IL6 MYC STAT3 VEGFA
50
Show member pathways
12.04 AKT1 MYC STAT3

GO Terms for Primary Effusion Lymphoma

Biological processes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.95 BCL6 MYC STAT3 VEGFA
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 AKT1 IL6 IRF4 MYC STAT3 VEGFA
3 cellular response to DNA damage stimulus GO:0006974 9.91 AKT1 BCL6 CASP3 MYC
4 negative regulation of cell proliferation GO:0008285 9.91 BCL6 CDKN1B IL6 STAT3
5 positive regulation of transcription, DNA-templated GO:0045893 9.91 AKT1 IL6 IRF4 MYC STAT3
6 inflammatory response GO:0006954 9.89 AKT1 BCL6 IL6 STAT3
7 positive regulation of gene expression GO:0010628 9.88 IL6 MYC STAT3 VEGFA
8 response to drug GO:0042493 9.86 CASP3 CDKN1B MYC STAT3
9 positive regulation of apoptotic process GO:0043065 9.83 AKT1 BCL6 CASP3 IL6 TNFSF10
10 response to hypoxia GO:0001666 9.79 CASP3 CDKN1B VEGFA
11 response to organic cyclic compound GO:0014070 9.77 CASP3 CDKN1B STAT3
12 cellular response to hypoxia GO:0071456 9.75 AKT1 MYC VEGFA
13 response to organic substance GO:0010033 9.72 AKT1 CASP3 STAT3
14 response to estradiol GO:0032355 9.71 CASP3 CDKN1B MYC STAT3
15 positive regulation of cell proliferation GO:0008284 9.7 AKT1 CDKN1B IL6 MYC STAT3 TCL1A
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IL6 STAT3 VEGFA
17 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.67 AKT1 IL6 TCL1A VEGFA
18 positive regulation of mesenchymal cell proliferation GO:0002053 9.65 MYC VEGFA
19 protein import into nucleus, translocation GO:0000060 9.64 AKT1 BCL6
20 positive regulation of DNA binding GO:0043388 9.64 IRF4 MYC
21 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.63 AKT1 VEGFA
22 endocrine pancreas development GO:0031018 9.63 AKT1 IL6
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.63 AKT1 IL6 MYC
24 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.62 CASP3 CDKN1B
25 positive regulation of cellular component movement GO:0051272 9.57 BCL6 VEGFA
26 interleukin-6-mediated signaling pathway GO:0070102 9.54 IL6 STAT3
27 positive regulation of ATP biosynthetic process GO:2001171 9.52 MYC STAT3
28 positive regulation of mitochondrial membrane potential GO:0010918 9.5 AKT1 MYC TCL1A
29 T-helper 17 cell lineage commitment GO:0072540 9.43 IL6 IRF4 STAT3
30 cellular response to organic cyclic compound GO:0071407 9.35 AKT1 CASP3 CDKN1B MYC STAT3
31 negative regulation of apoptotic process GO:0043066 9.28 AKT1 BCL6 CASP3 CDKN1B IL6 MYC

Molecular functions related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.46 AKT1 CDKN1B STAT3 TCL1A
2 identical protein binding GO:0042802 9.1 AKT1 BCL6 STAT3 TCL1A TNFSF10 VEGFA
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CASP3 CDKN1B
4 protein binding GO:0005515 10 AKT1 BCL6 CASP3 CDKN1B IL6 IRF4

Sources for Primary Effusion Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....